• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/12/21 2:51:54 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care
    Get the next $XAIR alert in real time by email
    SC 13G/A 1 d21192dsc13ga.htm BEYOND AIR, INC. BEYOND AIR, INC.

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13G

    INFORMATION STATEMENT TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b) (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (b)

    (Amendment No. 2)*

    Beyond Air, Inc.

    (Name of Issuer)

    Common Stock

    (Title of Class of Securities)

    08862L103

    (CUSIP Number)

                December 31, 2020            

    (Date of Event Which Requires Filing of This Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒       Rule 13d-1(b)

    ☐       Rule 13d-(c)

    ☐       Rule 13d-1 (d)

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


     

    CUSIP NO. 08862L103

     

      

    13G

     

     

    Page 2 of 10 Pages

     

     

     1   

     

    NAME OF REPORTING PERSON

     

    ALLIANZ GLOBAL INVESTORS U.S. HOLDINGS LLC

     

     2     

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

      

     

    (a) ☐

    (b) ☒

     3   

     

    SEC USE ONLY

     

     4    

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

     

    NUMBER OF SHARES  

    BENEFICIALLY

    OWNED BY

     

    EACH

    REPORTING

    PERSON

    WITH

        5     

     

    SOLE VOTING POWER

     

    0

     

        6     

     

    SHARED VOTING POWER

     

    0

     

        7     

     

    SOLE DISPOSITIVE POWER

     

    0

     

        8     

     

    SHARED DISPOSITIVE POWER

     

    0

     

     9   

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    0*

     

        
     10   

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

        

       ☐
     11   

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0.0%

     

        
     12   

     

    TYPE OF REPORTING PERSON

     

    HC, OO

     

     

        

    *See Item 4.


     

    CUSIP NO. 08862L103

     

      

    13G

     

     

    Page 3 of 10 Pages

     

     

     1    

     

    NAME OF REPORTING PERSON

     

    ALLIANZ GLOBAL INVESTORS GMBH

     

     2     

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

      

     

    (a) ☐

    (b) ☒

     3    

     

    SEC USE ONLY

     

     4    

     

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Germany

     

     

    NUMBER OF SHARES  

    BENEFICIALLY

    OWNED BY

     

    EACH

    REPORTING

    PERSON

    WITH:

        5     

     

    SOLE VOTING POWER

     

    0

     

        6     

     

    SHARED VOTING POWER

     

    0

     

        7     

     

    SOLE DISPOSITIVE POWER

     

    0

     

        8     

     

    SHARED DISPOSITIVE POWER

     

    0

     

      9   

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    0

     

     

     10   

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES                                     ☐

     

     

     11   

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0.0%

     

     12   

     

    TYPE OF REPORTING PERSON

     

    FI, OO

     


     

    CUSIP NO. 08862L103

     

      

    13G

     

     

    Page 4 of 10 Pages

     

     

    Item 1   (a)    Name of Issuer:
         Beyond Air, Inc.
      (b)    Address of Issuer’s Principal Executive Offices:
         825 East Gate Blvd., Suite 320
         Garden City, NY 11530
    Item 2   (a)    Name of Filers:
         Allianz Global Investors U.S. Holdings LLC (“AGI US Holdings”)
         Allianz Global Investors GmbH (“AGI GmbH”)
      (b)    Filers’ Address of Principal Business Office:
        

    AGI US Holdings: 1633 Broadway, New York, NY 10019

    AGI GmbH: Bockenheimer Landstrasse 42-44, Frankfurt, 2M 60323 Germany

      (c)    Filers’ Citizenship:
         AGI US Holdings: Delaware
         AGI GmbH: Germany
      (d)    Title of Class of Securities:
         Common Stock
      (e)    CUSIP Number:
         08862L103

    Item 3     If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b), check whether the person filing is a:

     

      (a)

    ☐ Broker or dealer registered under Section 15 of the Act;

     

      (b)

    ☐ Bank as defined in Section 3(a)(6) of the Act;

     

      (c)

    ☐ Insurance company as defined in Section 3(a)(19) of the Act;

     

      (d)

    ☐ Investment company registered under Section 8 of the Investment Company Act of 1940, as amended (the “Investment Company Act”);

     

      (e)

    ☐ Investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);

     

      (f)

    ☐ Employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);

     

      (g)

    ☒ Parent holding company or control person, in accordance with 13d-1(b)(ii)(G);

     

      (h)

    ☐ Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

     

      (i)

    ☐ Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;

     

      (j)

    ☒ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J); or

     

      (k)

    ☐ Group, in accordance with Rule13d-1(b)(1)(ii)(K);

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: German investment adviser.


     

    CUSIP NO. 08862L103

     

      

    13G

     

     

    Page 5 of 10 Pages

     

     

    Item 4                  Ownership.

     

      (a)

    Amount beneficially owned: 0

     

      (b)

    Percent of Class: 0.0%

     

      (c)

    Number of shares as to which such person has:

    (i)          Sole power to vote or direct the vote:

    Allianz Global Investors U.S. LLC (“AGI US”): 0

    AGI GmbH: 0

    (ii)          Shared power to vote: 0

    (iii)         Sole power to dispose or direct the disposition of:

    AGI US: 0

    AGI GmbH: 0

    (iv)         Shared power to dispose or direct the disposition of: 0

    Each of the entities named in this Item 4 (collectively, the “AGI Advisers”) is an investment adviser registered under Section 203 of the Investment Advisers Act of 1940, as amended, and a directly or indirectly wholly-owned subsidiary of AGI US Holdings except that AGI GmbH, an affiliate (but not a subsidiary) of AGI US Holdings, is a non-U.S. institution as described in Item 3(j).

    The securities reported in this Schedule 13G are held by investment advisory clients or discretionary accounts of which an AGI Adviser is the investment adviser. When an investment management contract (including a sub-advisory agreement) delegates to an AGI Adviser investment discretion or voting power over the securities held in the investment advisory accounts that are subject to that agreement, AGI US Holdings treats the AGI Adviser as having sole investment discretion or voting authority, as the case may be, for purposes of Schedule 13G filings unless the agreement specifies otherwise. Accordingly, this Schedule 13G reports that each AGI Adviser has sole investment discretion and voting authority over the securities covered by any such investment management agreement. Each AGI Adviser may be deemed to beneficially own the securities held by its clients or accounts within the meaning of rule 13d-3 under the Act. Because AGI US Holdings is the parent holding company of the AGI Advisers that are its subsidiaries, it may be deemed to beneficially own the securities held by those AGI Advisers’ clients or accounts.

    In accordance with SEC Release No. 34-39538 (January 12, 1998), this Schedule 13G reports the securities beneficially owned, or deemed to be beneficially owned, by certain subsidiaries and affiliates of AGI US Holdings. It does not include securities, if any, beneficially owned by affiliates of AGI US Holdings whose ownership of securities is disaggregated from that of AGI US Holdings and the AGI Advisers in accordance with that release.

    AGI US Holdings and the AGI Advisers believe that they do not constitute a “group” within the meaning of Rule 13d-5 under the Act and that they are not otherwise required to attribute to each other the beneficial ownership of the securities reported in this Schedule 13G held by any of them or by any persons or entities for whom or for which any AGI Adviser provides investment management services. Each of AGI US Holdings and the AGI Advisers also disclaims beneficial ownership of these securities except to the extent of that filer’s pecuniary interest therein.


     

    CUSIP NO. 08862L103

     

      

    13G

     

     

    Page 6 of 10 Pages

     

     

    Item 5

    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☒.

     

    Item 6

    Ownership of More than Five Percent on Behalf of Another Person.

    See Item 4. Each client of an AGI Adviser named in this Schedule 13G has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the securities reported herein. No one client holds more than five percent of such securities.

     

    Item 7

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

    See Items 3 and 4.

    Additionally, AGI US is an investment adviser as described in Item 3(e), and is registered under Section 203 of the Investment Advisers Act of 1940. AGI GmbH is non-U.S. institution as described in Item 3(j) and is a German investment adviser.

     

    Item 8

    Identification and Classification of Members of the Group.

    Not Applicable.

     

    Item 9

    Notice of Dissolution of Group.

    Not Applicable.

     

    Item 10

    Certification.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

    By signing below I certify that to the best of my knowledge and belief, the foreign regulatory scheme applicable to AGI GmbH is substantially comparable to the regulatory scheme applicable to the functionally equivalent U.S. institution(s). I also undertake to furnish to the Commission staff, upon request, information that would otherwise be disclosed in a Schedule 13D.

    Exhibits

    Exhibit A - Joint Filing Agreement

    Exhibit B - Limited Power of Attorney for U.S. Regulatory Reporting Obligations


     

    CUSIP NO. 08862L103

     

      

    13G

     

     

    Page 7 of 10 Pages

     

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: February 10, 2021

     

    ALLIANZ GLOBAL INVESTORS U.S. HOLDINGS LLC  
    By:   /s/ Paul Koo                                                                 
      Director and US Head of Business and Regulatory Compliance
    ALLIANZ GLOBAL INVESTORS GmbH
    By:   /s/ Paul Koo                                                                 
      Authorized Signatory


     

    CUSIP NO. 08862L103

     

      

    13G

     

     

    Page 8 of 10 Pages

     

     

    EXHIBIT A

    AGREEMENT REGARDING JOINT FILING

    OF STATEMENT ON SCHEDULE 13D OR 13G

    The undersigned agree to file jointly with the Securities and Exchange Commission (the “SEC”) any and all statements on Schedule 13D or Schedule 13G (and any amendments or supplements thereto) required under section 13(d) of the Securities Exchange Act of 1934, as amended, in connection with transactions by the undersigned in the securities of any issuer. For that purpose, Allianz Global Investors GmbH, a German corporation (“AGI GmbH”) hereby constitutes and appoints Allianz Global Investors U.S. Holdings LLC, a Delaware limited liability company, as its true and lawful agent and attorney-in-fact, with full power and authority for and on behalf of the undersigned to prepare or cause to be prepared, sign, file with the SEC and furnish to any other person all certificates, instruments, agreements and documents necessary to comply with section 13(d) and section 16(a) of the Securities Exchange Act of 1934, as amended, in connection with said transactions, and to do and perform every act necessary and proper to be done incident to the exercise of the foregoing power, as fully as AGI GmbH might or could do if personally present.

    Date: February 10, 2021

     

    ALLIANZ GLOBAL INVESTORS U.S. HOLDINGS LLC
    By:   /s/ Paul Koo                                                                 
      Director and US Head of Business and Regulatory Compliance
    ALLIANZ GLOBAL INVESTORS GmbH
    By:   /s/ Paul Koo                                                                 
      Authorized Signatory


     

    CUSIP NO. 08862L103

     

      

    13G

     

     

    Page 9 of 10 Pages

     

     

    EXHIBIT B

    LIMITED POWER OF ATTORNEY

    FOR

    U.S. REGULATORY REPORTING OBLIGATIONS

    Know all by these presents, that the undersigned hereby makes, constitutes and appoints Paul Koo as the undersigned’s true and lawful attorney-in-fact, with full power and authority as hereinafter described on behalf of and in the name, place and stead of the undersigned to:

    (A)       prepare, execute, acknowledge, deliver and file all U.S. regulatory reporting documentation (including any amendments thereto or any related documentation) with any regulatory agency, including but not limited to the United States Securities and Exchange Commission or any national securities exchanges as considered necessary or advisable under Sections 13 and 16 of the Securities Exchange Act of 1934 and the rules and regulations promulgated thereunder, as amended from time to time (the “Exchange Act”), and the Federal Reserve Bank of New York; and

    (B)       perform any and all other acts which in the discretion of such attorney-in-fact are necessary or desirable for and on behalf of the undersigned in connection with the foregoing.

    The undersigned acknowledges that:

    (1)       this Limited Power of Attorney authorizes, but does not require, such attorney-in-fact to act in his discretion on information provided to him without independent verification of such information;

    (2)       any documents prepared or executed by such attorney-in-fact on behalf of the undersigned pursuant to this Limited Power of Attorney will be in such form and will contain such information and disclosure as such attorney-in -fact, in his discretion, deems necessary or desirable;

    (3)       neither the Reporting Entity nor such attorney-in-fact assumes (a) any liability for the undersigned’s responsibility to comply with the requirements of the Exchange Act or (b) any liability of the undersigned for any failure to comply with such requirements; and

    (4)       this Limited Power of Attorney does not relieve the undersigned from responsibility for compliance with the undersigned’s obligations under the Exchange Act, including without limitation the reporting requirements under Sections 13 and 16 of the Exchange Act.

    The undersigned hereby gives and grants the foregoing attorney-in-fact full power and authority to do and perform all and every act and thing whatsoever requisite, necessary or appropriate to be done in and about the foregoing matters as fully to all intents and purposes as the undersigned might or could do if present, hereby ratifying all that such attorney-in-fact of, for and on behalf of the undersigned, shall lawfully do or cause to be done by virtue of this Limited Power of Attorney.

    This Limited Power of Attorney shall remain in full force and effect until revoked by the undersigned in a signed writing delivered to each such attorney-in-fact.


     

    CUSIP NO. 08862L103

     

      

    13G

     

     

    Page 10 of 10 Pages

     

     

    IN WITNESS WHEREOF, the undersigned has caused this Limited Power of Attorney to be executed as of this 13th day of October, 2014.

     

    /s/ Joon Tan                                                                            
    Signature
    Joon Tan                                                                                  
    Print Name
    European Head of Compliance
    Print Title

    Allianz Global Investors Europe GmbH (now known as Allianz Global Investors GmbH)

    Name of Institutional Investment Manager

    Get the next $XAIR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $XAIR

    DatePrice TargetRatingAnalyst
    6/25/2024Buy → Neutral
    BTIG Research
    7/28/2023$10.00Overweight
    Piper Sandler
    6/15/2023$15.00Buy
    BTIG Research
    11/12/2021$12.00 → $16.00Buy
    Truist Securities
    More analyst ratings

    $XAIR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • NeuroNOS Announces Groundbreaking Research Publication by its CSO Demonstrating Mechanism of Action in Alzheimer's Disease and Reinforcing Platform's Strength Across Neurological Disorders

      BOSTON, April 01, 2025 (GLOBE NEWSWIRE) -- NeuroNOS, a pioneering biopharmaceutical company developing transformative treatments for complex neurological disorders, including Autism Spectrum Disorder (ASD), brain cancers, and Alzheimer's disease, and a subsidiary of Beyond Air (NASDAQ:XAIR), proudly announces the publication of breakthrough research by its Chief Scientific Officer, Prof. Haitham Amal, in Translational Psychiatry, a peer-reviewed medical journal published by Nature Publishing Group. The article, which is titled, "Shared Early Molecular Mechanisms Revealed in P301S and 5xFAD Alzheimer's Disease Mouse Models," presents compelling evidence of a novel mechanism in the early sta

      4/1/25 8:00:00 AM ET
      $XAIR
      Medical/Dental Instruments
      Health Care
    • NeuroNOS Secures $2.0 Million in Funding to Advance Development of an Innovative Autism Therapy

      First-in-human studies anticipated to begin in 2026 Engaged a top tier U.S. based contract manufacturer to ensure the highest standards of quality Currently in the advanced stages of formulation development for subcutaneous injection, with plans for an oral formulation BOSTON, March 24, 2025 (GLOBE NEWSWIRE) -- NeuroNOS, a pioneering biopharmaceutical company focused on developing transformative treatments for Autism Spectrum Disorder (ASD) and other complex neurological conditions, including Alzheimer's disease and brain cancers, and a subsidiary of Beyond Air (NASDAQ:XAIR), has secured an initial $2 million in equity financing from private investors as part of a larger funding round.

      3/24/25 4:05:00 PM ET
      $XAIR
      Medical/Dental Instruments
      Health Care
    • Beyond Cancer Announces Approval by the Israeli Ministry of Health to Conduct a Phase 1b Clinical Trial Utilizing Low Volume Ultra-High Concentration Nitric Oxide (LV UNO) in Combination with Anti-PD-1 Therapy

      The Phase 1b study will evaluate LV UNO in unresectable cutaneous or subcutaneous histologically confirmed primary or metastatic solid tumor cancer patients that have progressed or have prolonged stable disease on single agent PD-1 inhibitorsThe primary objective of the Phase 1b study is to assess preliminary efficacy by objective response rate (ORR) and duration of response (DOR) per RECIST version 1.1 and secondarily immune-related response via iRECISTThe study will recruit patients from four sites across Israel HAMILTON, Bermuda, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., a clinical-stage biotechnology company developing ultra-high concentration nitric oxide (UNO) as an imm

      12/3/24 4:05:00 PM ET
      $XAIR
      Medical/Dental Instruments
      Health Care

    $XAIR
    SEC Filings

    See more
    • SEC Form DEF 14A filed by Beyond Air Inc.

      DEF 14A - Beyond Air, Inc. (0001641631) (Filer)

      5/5/25 4:45:04 PM ET
      $XAIR
      Medical/Dental Instruments
      Health Care
    • SEC Form PRE 14A filed by Beyond Air Inc.

      PRE 14A - Beyond Air, Inc. (0001641631) (Filer)

      4/25/25 5:20:21 PM ET
      $XAIR
      Medical/Dental Instruments
      Health Care
    • Beyond Air Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

      8-K - Beyond Air, Inc. (0001641631) (Filer)

      3/28/25 4:05:16 PM ET
      $XAIR
      Medical/Dental Instruments
      Health Care

    $XAIR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Beyond Air downgraded by BTIG Research

      BTIG Research downgraded Beyond Air from Buy to Neutral

      6/25/24 8:04:46 AM ET
      $XAIR
      Medical/Dental Instruments
      Health Care
    • Piper Sandler initiated coverage on Beyond Air with a new price target

      Piper Sandler initiated coverage of Beyond Air with a rating of Overweight and set a new price target of $10.00

      7/28/23 7:37:57 AM ET
      $XAIR
      Medical/Dental Instruments
      Health Care
    • BTIG Research initiated coverage on Beyond Air with a new price target

      BTIG Research initiated coverage of Beyond Air with a rating of Buy and set a new price target of $15.00

      6/15/23 7:39:48 AM ET
      $XAIR
      Medical/Dental Instruments
      Health Care

    $XAIR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Operating Officer Gaul Michael A.

      4 - Beyond Air, Inc. (0001641631) (Issuer)

      3/28/25 5:12:57 PM ET
      $XAIR
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Lee Yoori

      4 - Beyond Air, Inc. (0001641631) (Issuer)

      3/28/25 5:12:58 PM ET
      $XAIR
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Lucera Erick

      4 - Beyond Air, Inc. (0001641631) (Issuer)

      3/28/25 5:12:59 PM ET
      $XAIR
      Medical/Dental Instruments
      Health Care

    $XAIR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Beyond Air Inc.

      SC 13G/A - Beyond Air, Inc. (0001641631) (Subject)

      10/9/24 1:35:29 PM ET
      $XAIR
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Beyond Air Inc.

      SC 13G - Beyond Air, Inc. (0001641631) (Subject)

      10/3/24 3:09:56 PM ET
      $XAIR
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Beyond Air Inc.

      SC 13G - Beyond Air, Inc. (0001641631) (Subject)

      3/7/24 12:29:51 PM ET
      $XAIR
      Medical/Dental Instruments
      Health Care

    $XAIR
    Financials

    Live finance-specific insights

    See more

    $XAIR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $XAIR
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • Beyond Air® Schedules Second Fiscal Quarter 2025 Financial Results Conference Call and Webcast

      GARDEN CITY, N.Y., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR) ("Beyond Air" or the "Company"), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients, today announced that it plans to report the financial results for the second quarter of its fiscal year 2025 ended September 30, 2024 on Monday, November 11, 2024 after the market closes. Conference Call & WebcastMonday, November 11th @ 4:30 PM ETDomestic: 1-877-407-0784International: 1-201-689-8560Conference ID: 13749670Webcast: A webcast of the live conference call can be accessed by visiting the Eve

      10/29/24 4:22:08 PM ET
      $XAIR
      Medical/Dental Instruments
      Health Care
    • Beyond Air® Reports Financial Results for Fourth Fiscal Quarter and Year-End 2022

      LungFit® PH received FDA approval for the treatment of term and near-term neonates with hypoxic respiratory failure on June 28, 2022 and the first phase of U.S. commercial launch has begun Presented positive data for high-concentration nitric oxide (NO) with LungFit® PRO in hospitalized patients with community-acquired viral pneumonia, including COVID-19, at ECCMID 2022 Presented positive long-term safety data for high-concentration NO at PAS 2022 in infants hospitalized with bronchiolitis Presented positive updated interim data from the ongoing at-home LungFit® GO pilot study for nontuberculous mycobacterial lung disease at ATS 2022 Patient screening has begun for the Phase I trial of

      6/28/22 4:10:00 PM ET
      $XAIR
      Medical/Dental Instruments
      Health Care
    • Beyond Air® Announces Fiscal Year End 2022 Financial Results Conference Call and Webcast Moved to Tuesday, June 28th

      GARDEN CITY, New York, June 14, 2022 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced that it has rescheduled the reporting of the financial results for its fiscal fourth quarter and year ended March 31, 2022 to Tuesday, June 28, 2022. The Company's management team will also host its quarterly conference call and webcast at 4

      6/14/22 4:30:00 PM ET
      $XAIR
      Medical/Dental Instruments
      Health Care
    • Director Carey Robert bought $250,050 worth of shares (1,000,000 units at $0.25), increasing direct ownership by 33% to 4,076,864 units (SEC Form 4)

      4 - Beyond Air, Inc. (0001641631) (Issuer)

      3/17/25 8:15:33 AM ET
      $XAIR
      Medical/Dental Instruments
      Health Care
    • Chief Operating Officer Gaul Michael A. bought $2,294 worth of shares (6,000 units at $0.38), increasing direct ownership by 7% to 94,150 units (SEC Form 4)

      4 - Beyond Air, Inc. (0001641631) (Issuer)

      2/21/25 5:00:14 PM ET
      $XAIR
      Medical/Dental Instruments
      Health Care
    • Director Carey Robert bought $744,662 worth of shares (1,476,626 units at $0.50) (SEC Form 4)

      4 - Beyond Air, Inc. (0001641631) (Issuer)

      10/1/24 9:58:10 PM ET
      $XAIR
      Medical/Dental Instruments
      Health Care
    • July 1, 2022 - FDA Roundup: July 1, 2022

      For Immediate Release: July 01, 2022 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced a request for nominations for consumer representatives to serve on advisory committees and panels for which vacancies currently exist or are expected to occur in the near future. The FDA relies on our many advisory committees to help us

      7/1/22 11:54:25 AM ET
      $XAIR
      Medical/Dental Instruments
      Health Care

    $XAIR
    Leadership Updates

    Live Leadership Updates

    See more
    • Beyond Cancer™ Announces the Appointment of Jedidiah Monson, M.D. to Chief Medical Officer

      Dr. Monson is a board-certified radiation oncologist and brings over 25 years of clinical oncology experience to Beyond Cancer. Dr. Monson is a founding partner and President of California Cancer Associates for Research & Excellence (cCARE), the largest private oncology practice in California. HAMILTON, Bermuda, June 01, 2022 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ:XAIR) that is focused on developing ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced the appointment of Jedidiah Monson, M.D. to the position of Chief Medical Officer, effective June 1, 2022. "We are excited to appoint Dr. Monson as

      6/1/22 7:00:00 AM ET
      $XAIR
      Medical/Dental Instruments
      Health Care
    • Beyond Cancer, Ltd. Appoints Susan Howell Jones, CPA as Chief Financial Officer

      HAMILTON, Bermuda, May 17, 2022 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ:XAIR) that is focused on developing ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced the appointment of Susan Howell Jones, CPA as Chief Financial Officer. Ms. Jones joins Beyond Cancer™ with over 30 years of international and operational financial leadership experience, including 20 years within the bioscience sector of BASF, a globally recognized chemical company. In her role as Senior Manager of Operational Accounting she was a key member of the implementation team responsible for the $4B acquisition of American Cyanamid. Follow

      5/17/22 7:00:00 AM ET
      $XAIR
      Medical/Dental Instruments
      Health Care
    • Beyond Air® Expands Leadership Team with the Appointment of Dr. Andrew Colin to Chief Medical Officer

      Dr. Colin brings four decades of clinical experience in pediatric pulmonology to Beyond Air, with research spanning respiratory physiology, Cystic Fibrosis, and lung infections culminating in over 120 peer-reviewed publications and 250 global lectures As a board-certified pediatric pulmonologist, Dr. Colin has been an active member of Beyond Air's Scientific Advisory Board since 2013 Dr. Colin has participated in over 20 clinical trials, including studies sponsored by the National Institutes of Health, Genentech, GlaxoSmithKline, and the Cystic Fibrosis Foundation's Therapeutic Development Network GARDEN CITY, N.Y., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR), a c

      12/1/21 8:00:00 AM ET
      $XAIR
      Medical/Dental Instruments
      Health Care